Dr. Jerome Adams Shares How to Create a Face Covering
Our Surgeon General, Dr. Jerome Adams, shares ways to create your own face covering in a few easy steps.
Our Surgeon General, Dr. Jerome Adams, shares ways to create your own face covering in a few easy steps.
The LRG was featured in the MyPART Minute April edition, in the Advocacy Spotlight section, which detailed our mission, core values, and the story of our collaboration with the National Institutes of Health to create the annual NIH Pediatric and Wildtype GIST Clinic.
Conversations with the Life Raft Group will debuted 4/2/2020 at 1 pm. Our first featured guest was Norman J. Scherzer, the Executive Director of the Life Raft Group. With his background at the CDC as Assistant Commissioner of Health for NYC, Norman is an excellent resource for discussing strategies for coping with COVID-19.
In this issue of LRG Science, the relationship between overall survival (OS) and access to treatments after imatinib failure is explored. In 2019, the LRG published this research in Clinical Sarcoma Research and this issue includes commentary from experts. LRG Science endeavors to be a respected source of timely, science-based information built on real world data designed for those whose focus is to increase patient survival from GIST and other cancers.
As the number of people who have fallen ill grows, the FDA announced approval if the use of two anti-malaria drugs for coronavirus.
This page is a collection of information for our patients on COVID-19 and the coronavirus crisis of 2020 some of which was written by the LRG for patient support and some authored by outside authorities and curated by the LRG.
Nuestro colaborador global, Alianza GIST comparte el artículo "El tratamiento de pacientes con cáncer y la contención de COVID-19: experiencias de Italia "por el Dr. Giuseppe Curigliano publicado en el ASCO Daily News. Este artículo también está disponible en inglés.
In this critical time, the FDA Oncology Center of Excellence wants you to know that we are here for patients with cancer and their health care providers and we will do everything we can to help you through the coronavirus crisis.
During this webcast presentation, Dr. Michael Heinrich will discuss these two new treatment options for advanced GIST. Dr. Heinrich will explain how each of these drugs works to target mutations for which there has previously been no targeted treatment and discuss the current coronavirus outbreak.
LRG members Jennifer & Owen Moore give their perspective on participating in the Phase I BLU-285 trial at OSHU with Dr. Michael Heinrich. After three other drug treatment lines and faced with several growing tumors, the BLU-285 (avapritinib) trial was Owen’s best option.